CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$8.75
0.28 (3.31%)
▲
5d:
+13.34%
30d:
+7.1%
90d:
+24.64%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 5.4/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 83.4% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 83.4% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $8.75, which is considered fair relative to its 30-day fair value range of $8.09 to $8.75. From a valuation perspective, the stock is trading at a premium (Forward PE: 101.7) compared to its historical average (16.5). At these levels, the market is pricing in 83.4% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.50, while resistance sits at $9.06. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.20 (+73.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.50, while resistance sits at $9.06. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.20 (+73.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.09 -
$8.75
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 73.7% below Wall St target ($15.20)
- BEARISH: Market expects 83.4% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$8.09 -
$8.75
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.50
Resistance Level
$9.06
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
101.74
Wall Street Target
$15.20
(+73.7%)
Revenue Growth (YoY)
226.1%
Earnings Growth (YoY)
42.8%
Profit Margin
45.2%
Valuation Premium vs History
+83.4% premium
PE vs Historical
101.7 vs 16.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+83.4%
(market-implied from PE analysis)
1-Year Target
$13.12
(+50%)
2-Year Target
$19.69
(+125%)
3-Year Target
$29.53
(+238%)
3-Yr Target (if PE normalizes)
(PE: 102→17)
PE COMPRESSION
$4.79
(-45%)
Significant PE compression expected
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 101.7, Growth: -82.8%)
$6.38
(+-27%)
Base:
(SPY PE: 21.8, Growth: -82.8%)
$1.37
(-84%)
Bear:
(PE: 16.5, Growth: -82.8%)
$1.03
(-88%)
📈
Valuation based on Current Earnings
Trailing PE: 3.90 | Current EPS (TTM): $2.17
Bull Case
$4.66
(-47%)
Analyst growth -50.0%, PE expands to 4.3
Base Case
$4.23
(-52%)
Market implied -50.0%, PE stable at 3.9
Bear Case
$5.76
(-34%)
Severe decline -20.0%, PE contracts to 3.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 02, 2026 10:56 PM ET
Data refreshes hourly during market hours. Next update: 11:56 PM
Data refreshes hourly during market hours. Next update: 11:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
